Highlight 3 in breast cancer
Prof. François Duhoux from Cliniques Universitaires St Luc in Brussels shares his insights on the most exciting presentations in the oral abstract session on metastatic breast cancer.
He discusses the SONIA trial, the PALMIRA trial and the final overall survival analysis of the TROPiCS-02 study in patients with HR+, HER2- advanced breast cancer.
He also touches upon dynamics and type of ESR1 mutations in the PADA-1 trial, as well as the X-7/7 trial with a fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer. An age-specific pooled analysis of T‑DXd from DESTINY-Breast01, -02, and -03 studies is also included in his selection of highlights. Finally, Prof. Duhoux shares his view on the impact of repeat biopsies on the HER2-low status among patients with triple negative breast cancer.
With the educational support of:
